Xeris Pharmaceuticals’ $98.3 Million Initial Public Offering

Goodwin advised Xeris Pharmaceuticals on the deal Xeris Pharmaceuticals (“XERS”), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and…